Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Loss of the Cyclin-Dependent Kinase Inhibitor 1 in the Context of Brachyury-Mediated Phenotypic Plasticity Drives Tumor Resistance to Immune Attack.

Hamilton DH, McCampbell KK, Palena C.

Front Oncol. 2018 May 3;8:143. doi: 10.3389/fonc.2018.00143. eCollection 2018.

2.

Brachyury-YAP Regulatory Axis Drives Stemness and Growth in Cancer.

Shah SR, David JM, Tippens ND, Mohyeldin A, Martinez-Gutierrez JC, Ganaha S, Schiapparelli P, Hamilton DH, Palena C, Levchenko A, Quiñones-Hinojosa A.

Cell Rep. 2017 Oct 10;21(2):495-507. doi: 10.1016/j.celrep.2017.09.057.

3.

Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.

Heery CR, Palena C, McMahon S, Donahue RN, Lepone LM, Grenga I, Dirmeier U, Cordes L, Marté J, Dahut W, Singh H, Madan RA, Fernando RI, Hamilton DH, Schlom J, Gulley JL.

Clin Cancer Res. 2017 Nov 15;23(22):6833-6845. doi: 10.1158/1078-0432.CCR-17-1087. Epub 2017 Aug 30.

PMID:
28855356
4.

Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition.

Hamilton DH, David JM, Dominguez C, Palena C.

Cells Tissues Organs. 2017;203(2):128-138. doi: 10.1159/000446495. Epub 2017 Feb 20. Review.

5.

Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer.

Hamilton DH, Roselli M, Ferroni P, Costarelli L, Cavaliere F, Taffuri M, Palena C, Guadagni F.

Endocr Relat Cancer. 2016 Oct;23(10):783-796. doi: 10.1530/ERC-16-0037.

6.

The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance.

David JM, Dominguez C, Hamilton DH, Palena C.

Vaccines (Basel). 2016 Jun 24;4(3). pii: E22. doi: 10.3390/vaccines4030022. Review.

7.

Targeting Estrogen Receptor Signaling with Fulvestrant Enhances Immune and Chemotherapy-Mediated Cytotoxicity of Human Lung Cancer.

Hamilton DH, Griner LM, Keller JM, Hu X, Southall N, Marugan J, David JM, Ferrer M, Palena C.

Clin Cancer Res. 2016 Dec 15;22(24):6204-6216. Epub 2016 Jun 7.

8.

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.

Fernando RI, Hamilton DH, Dominguez C, David JM, McCampbell KK, Palena C.

Oncotarget. 2016 Jul 5;7(27):42031-42044. doi: 10.18632/oncotarget.9662.

9.

MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition.

David JM, Hamilton DH, Palena C.

Oncoimmunology. 2016 Jan 6;5(4):e1117738. eCollection 2016 Apr.

10.

Immune Targeting of Tumor Epithelial-Mesenchymal Transition via Brachyury-Based Vaccines.

Palena C, Hamilton DH.

Adv Cancer Res. 2015;128:69-93. doi: 10.1016/bs.acr.2015.04.001. Epub 2015 May 12. Review.

PMID:
26216630
11.
12.

Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis.

Palena C, Roselli M, Litzinger MT, Ferroni P, Costarelli L, Spila A, Cavaliere F, Huang B, Fernando RI, Hamilton DH, Jochems C, Tsang KY, Cheng Q, Lyerly HK, Schlom J, Guadagni F.

J Natl Cancer Inst. 2014 May 9;106(5). pii: dju054. doi: 10.1093/jnci/dju054.

13.

WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition.

Hamilton DH, Huang B, Fernando RI, Tsang KY, Palena C.

Cancer Res. 2014 May 1;74(9):2510-9. doi: 10.1158/0008-5472.CAN-13-1894. Epub 2014 Mar 13.

14.
15.

Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process.

Ardiani A, Gameiro SR, Palena C, Hamilton DH, Kwilas A, King TH, Schlom J, Hodge JW.

Cancer Res. 2014 Apr 1;74(7):1945-57. doi: 10.1158/0008-5472.CAN-13-2045. Epub 2014 Feb 11.

16.

Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine.

Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, Ardiani A, Apelian D, Schlom J, Palena C.

Oncotarget. 2013 Oct;4(10):1777-90.

17.

The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies.

Huang B, Cohen JR, Fernando RI, Hamilton DH, Litzinger MT, Hodge JW, Palena C.

Cell Death Dis. 2013 Jun 20;4:e682. doi: 10.1038/cddis.2013.208.

18.

An autocrine loop between TGF-β1 and the transcription factor brachyury controls the transition of human carcinoma cells into a mesenchymal phenotype.

Larocca C, Cohen JR, Fernando RI, Huang B, Hamilton DH, Palena C.

Mol Cancer Ther. 2013 Sep;12(9):1805-15. doi: 10.1158/1535-7163.MCT-12-1007. Epub 2013 Jun 19.

19.

Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment.

Palena C, Hamilton DH, Fernando RI.

Future Oncol. 2012 Jun;8(6):713-22. doi: 10.2217/fon.12.59. Review.

20.

Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas.

Hamilton DH, Litzinger MT, Fernando RI, Huang B, Palena C.

Semin Oncol. 2012 Jun;39(3):358-66. doi: 10.1053/j.seminoncol.2012.02.005. Review.

21.

IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells.

Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C.

Cancer Res. 2011 Aug 1;71(15):5296-306. doi: 10.1158/0008-5472.CAN-11-0156. Epub 2011 Jun 8.

22.

Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells.

Palena C, Fernando RI, Litzinger MT, Hamilton DH, Huang B, Schlom J.

Exp Biol Med (Maywood). 2011 May 1;236(5):537-45. doi: 10.1258/ebm.2011.010367. Epub 2011 Mar 22. Review.

23.

The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells.

Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C.

J Clin Invest. 2010 Feb;120(2):533-44. doi: 10.1172/JCI38379. Epub 2010 Jan 11.

24.

Different immune correlates associated with tumor progression and regression: implications for prevention and treatment of cancer.

Hamilton DH, Bretscher PA.

Cancer Immunol Immunother. 2008 Aug;57(8):1125-36. doi: 10.1007/s00262-007-0442-9. Epub 2008 Jan 10.

PMID:
18188562
25.

The Epidemic Intelligence Service: The Centers for Disease Control and Prevention's Disease Detectives.

Hamilton DH.

Virtual Mentor. 2006 Apr 1;8(4):261-4. doi: 10.1001/virtualmentor.2006.8.4.mhst2-0604. No abstract available.

PMID:
23241628
27.

Large cooperativity in the removal of iron from transferrin at physiological temperature and chloride ion concentration.

Hamilton DH, Turcot I, Stintzi A, Raymond KN.

J Biol Inorg Chem. 2004 Dec;9(8):936-44. Epub 2004 Oct 29.

PMID:
15517438
28.
29.

Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation.

Revanur VK, Jardine AG, Kingsmore DB, Jaques BC, Hamilton DH, Jindal RM.

Clin Transplant. 2001 Apr;15(2):89-94.

PMID:
11264633
30.

Outcome for arterio-venous fistula at the elbow for haemodialysis.

Revanur VK, Jardine AG, Hamilton DH, Jindal RM.

Clin Transplant. 2000 Aug;14(4 Pt 1):318-22.

PMID:
10945202
31.

Cat-scratch disease--Connecticut, 1992-1993.

Hamilton DH, Zangwill KM, Hadler JL, Cartter ML.

J Infect Dis. 1995 Aug;172(2):570-3.

PMID:
7622908
32.

Cat scratch disease in Connecticut. Epidemiology, risk factors, and evaluation of a new diagnostic test.

Zangwill KM, Hamilton DH, Perkins BA, Regnery RL, Plikaytis BD, Hadler JL, Cartter ML, Wenger JD.

N Engl J Med. 1993 Jul 1;329(1):8-13.

33.

Characterization of the non-permissive infection of rabbit cornea cells by vesicular stomatitis virus.

Hamilton DH, Moyer RW, Moyer SA.

J Gen Virol. 1980 Aug;49(2):273-87.

PMID:
6255068
34.

Ground rupture in the baldwin hills.

Hamilton DH, Meehan RL.

Science. 1971 Apr 23;172(3981):333-44. No abstract available.

PMID:
17756033
35.

Power plants: effects of chlorination on estuarine primary production.

Hamilton DH Jr, Flemer DA, Keefe CW, Mihursky JA.

Science. 1970 Jul 10;169(3941):197-8.

PMID:
5427354
36.

Thermal pollution of cayuga lake.

Hamilton DH.

Science. 1969 Feb 7;163(3867):517. No abstract available.

PMID:
17750878
37.

Glaucoma control program in Minnesota.

HAMILTON DH.

Sight Sav Rev. 1947 Spring;17(1):30-3. No abstract available.

PMID:
20251009

Supplemental Content

Loading ...
Support Center